Skip to main content

Anthrax Vaccine: Safety and Efficacy Issues

T-NSIAD-00-48 Published: Oct 12, 1999. Publicly Released: Oct 12, 1999.
Jump To:
Skip to Highlights

Highlights

Pursuant to a congressional request, GAO discussed the results of its ongoing examination of the safety and efficacy of the anthrax vaccine, focusing on the: (1) need for a six-shot regimen and annual booster shots; (2) long- and short-term safety of the vaccine; (3) efficacy of the vaccine; (4) extent to which problems the Food and Drug Administration (FDA) found in the vaccine production facility in Michigan could compromise the safety, efficacy, and quality of the vaccine; and (5) effects of the anthrax vaccine on children, pregnant women or lactating women.

Full Report

Office of Public Affairs

Topics

Biological warfareChemical agentsBiological agentsAnthraxChemical warfareImmunization programsImmunization servicesMilitary personnelProduct evaluationProduct safetyQuality controlSafety standards